Peptide Drugs for Pain Management: Conotoxins, CGRP Inhibitors, and Chronic Pain Therapies

Pain is one of the most common reasons people seek medical care. Chronic pain affects more than 1.5 billion people worldwide.

Managing pain is hard. Current pain medicines, especially opioids, carry serious risks of addiction and overdose. There is a huge need for better, safer pain treatments.

Peptides offer a promising path forward. They can target pain pathways with great precision, which means better pain relief with fewer side effects.

The Problem With Current Pain Treatments

Opioid drugs like morphine and oxycodone are effective pain relievers. But they also cause addiction, constipation, sedation, and deadly overdoses.

More than 80,000 Americans died from opioid overdose in 2023. Finding safer pain medicines is one of the top priorities in medicine.

NSAIDs (anti-inflammatory drugs) like ibuprofen can cause stomach bleeds and kidney damage with long-term use. Gabapentinoids cause sedation and cognitive fog.

Peptide pain medicines are designed to be highly specific. They hit the exact target responsible for pain and leave everything else alone.

The cone snail, a small sea creature, has been killing people for thousands of years. But its venom is also one of the richest sources of pain-relieving peptides ever discovered.

Opioid Peptides: The Body's Natural Pain Killers

The body makes its own opioid peptides. These are called endogenous opioids and include:

• Endorphins (beta-endorphin)
• Enkephalins (met-enkephalin, leu-enkephalin)
• Dynorphins
• Endomorphins

These natural peptides bind to the same opioid receptors as morphine. But because they are broken down quickly in the body, they cannot be used directly as medicines.

Scientists are developing modified versions of these peptides that last longer and have better safety profiles. Endomorphin-2 analogs, for example, provide strong pain relief in animal models with much less constipation and addiction potential than morphine.

Biased Opioid Agonist Peptides

One exciting approach is biased agonism. Opioid receptors can produce two types of signals when activated. One signal gives pain relief. The other causes side effects.

Biased opioid peptides are designed to only trigger the pain-relief signal, not the side-effect signal. This could give the benefits of opioids without the addiction and respiratory depression.

Conotoxins: Venom-Derived Peptide Pain Killers

Conotoxins are peptides from cone snail venom. Cone snails paralyze their prey with these powerful chemicals.

But many conotoxins are also amazing pain-fighting medicines. They work on ion channels and receptors in the nervous system that control pain signals.

Ziconotide (Prialt)

Ziconotide, sold under the brand name Prialt, is the first FDA-approved conotoxin drug. It was approved in 2004 for severe chronic pain.

It is a 25-amino acid peptide that blocks N-type calcium channels in the spinal cord. These channels are critical for sending pain signals from the body to the brain.

Ziconotide is extremely potent. It is given by continuous infusion directly into the spinal fluid (intrathecal). It provides dramatic pain relief for patients with cancer pain or neuropathic pain who have failed all other treatments.

Expert Quote: "Ziconotide proved that a peptide derived from a deadly venom could become a life-changing medicine. It opened the door to a whole new class of peptide pain drugs." - Dr. Michael Yaksh, University of California San Diego

Conotoxins in Development

Many other conotoxins are in development for pain. Key targets include:

Conotoxin	Target	Pain Type	Development Stage
Ziconotide (Prialt)	N-type Ca2+ channel (Cav2.2)	Severe chronic pain	FDA approved
ACV1 (alpha-conotoxin Vc1.1)	Alpha-9/10 nAChR, GABA-B receptor	Neuropathic pain	Phase 2
Conkunitzin-S1	Kv1.7 potassium channel	Pain	Preclinical
MrVIB (mu-conotoxin)	Nav1.8 sodium channel	Inflammatory pain	Preclinical
Alpha-conotoxin RgIA	Alpha-9 nAChR	CIPN, neuropathic pain	Preclinical

ACV1 (alpha-conotoxin Vc1.1) has reached Phase 2 clinical trials. It targets nicotinic acetylcholine receptors and GABA-B receptors, reducing pain signals with a very good safety profile.

CGRP Inhibitor Peptides for Migraine Pain

CGRP (calcitonin gene-related peptide) is a signaling molecule that plays a key role in migraine pain. When CGRP is released in the brain, it causes blood vessels to dilate and pain signals to fire intensely.

Blocking CGRP has transformed migraine treatment. The first approved CGRP inhibitors were antibodies. But peptide-based CGRP receptor antagonists (gepants) are now also available.

Gepants: Peptide-Derived CGRP Blockers

Gepants are small molecule drugs that evolved from peptide CGRP receptor antagonists. Examples include:

• Ubrogepant (Ubrelvy): FDA-approved for acute migraine treatment
• Atogepant (Qulipta): FDA-approved for migraine prevention
• Rimegepant (Nurtec): FDA-approved for both acute and preventive treatment

These drugs work by blocking the CGRP receptor. They are taken as pills and provide fast migraine relief without the blood vessel constriction that older migraine drugs (triptans) cause.

For people with heart disease or stroke risk, gepants are a much safer option than triptans.

CGRP-blocking therapies have reduced migraine frequency by 50% or more in about half of patients who try them. This represents a major leap forward in migraine care.

Neurotensin Peptides for Pain

Neurotensin is a natural brain peptide that reduces pain. It works through different receptors than opioids, so it does not cause opioid-like addiction.

Synthetic neurotensin analogs are being developed. They have shown strong pain relief in animal models for inflammatory and neuropathic pain without sedation or addiction.

One promising compound is JMV 431, a neurotensin analog that showed significant pain relief in studies of inflammatory pain. It is being refined for clinical development. For authoritative context, see the NIH National Institute of Neurological Disorders and Stroke pain resources.

SP (Substance P) and Pain

Substance P is a peptide neurotransmitter that sends pain signals. Blocking substance P is another way to reduce pain.

Several peptide antagonists of the NK1 receptor (the receptor for substance P) have been developed. Some have been tested in clinical trials for pain, but results have been mixed. The research continues as scientists refine these molecules.

Peptide Approaches for Neuropathic Pain

Neuropathic pain is caused by damage to nerves themselves. It often feels like burning, stabbing, or electric shock sensations.

It is one of the hardest types of pain to treat. Current drugs help some patients but fail many others.

New peptide targets for neuropathic pain include:

Target	Peptide Type	Mechanism	Stage
Nav1.7 sodium channel	Huwentoxin analogs	Blocks pain signals	Preclinical
Nav1.8 sodium channel	Conotoxin-based	Selective nerve block	Preclinical
TRPV1 channel	Capsaicin-related peptides	Desensitization	Clinical
Delta-opioid receptor	Endomorphin analogs	Pain signaling	Preclinical
GLP-1 receptor	GLP-1 analogs	Neuroprotection	Preclinical/early clinical

Spider Venom Peptides

Like cone snails, spiders also make peptides that target pain-related ion channels. Huwentoxin-IV and related peptides from tarantula venom block Nav1.7, a sodium channel that is essential for pain signaling.

People born without working Nav1.7 channels feel no pain at all (a rare genetic condition). This makes Nav1.7 one of the most validated targets in pain medicine.

Peptides that selectively block Nav1.7 could offer powerful pain relief without numbing all sensation. Several are in preclinical development.

Advantages of Peptide Pain Medicines Over Traditional Drugs

Feature	Opioids	NSAIDs	Peptide Pain Drugs
Efficacy	Very high	Moderate	High to very high
Addiction risk	Very high	Low	Very low
Side effects	Severe	Moderate	Generally low
Mechanism specificity	Low	Low	High
Overdose risk	High	Low	Very low
Tolerance development	Common	Rare	Rare (most)

FAQs

What are conotoxins and why are they used in pain management?

Conotoxins are peptides from cone snail venom. They are powerful blockers of ion channels and receptors in the nervous system that carry pain signals. Because they are so precise in how they work, they can block pain without many of the side effects of traditional pain drugs. Ziconotide was the first conotoxin approved as a medicine.

How do CGRP inhibitor peptides treat migraines?

CGRP is a signaling molecule released during migraines that causes intense pain and blood vessel changes. CGRP inhibitor peptides, or gepants, block the receptor that CGRP binds to. This stops the chain of events that leads to migraine pain. Gepant drugs like ubrogepant and rimegepant are now FDA approved for migraine treatment.

Are there peptide alternatives to opioids for chronic pain?

Yes, several peptide alternatives are in development. These include biased opioid peptides (that give pain relief without addiction), conotoxins, neurotensin analogs, and spider venom-derived ion channel blockers. Some are already approved (like ziconotide), while others are in clinical or preclinical trials.

What is neuropathic pain and how can peptides help?

Neuropathic pain comes from damaged nerves. It feels different from normal pain and is harder to treat. Peptides help by blocking specific ion channels (like Nav1.7 or Nav1.8) that carry pain signals in damaged nerves. Targeting these channels precisely can reduce neuropathic pain without affecting other nerve functions.

How is ziconotide given and who is it for?

Ziconotide is delivered directly into the spinal fluid through a pump implanted in the abdomen. It cannot be taken as a pill because it does not survive digestion or cross into the spinal cord from the blood. It is used for severe, treatment-resistant chronic pain, particularly in cancer patients and those with failed back surgery syndrome.

Find Peptide Pain Research Experts With PeptideStaff

Pain peptide research requires specialized scientists across neuropharmacology, peptide chemistry, toxinology, and clinical pain medicine. These are rare and highly specialized profiles.

PeptideStaff connects pharma and biotech organizations with the specialized peptide talent they need to advance their pain management programs.

Contact PeptideStaff today to find your next peptide pain management research expert.